Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line

Kazuhiko Ochiai, Daigo Azakami, Masami Morimatsu, Hinako Hirama, Shota Kawakami, Takayuki Nakagawa, Masaki Michishita, Ai S. Egusa, Takanori Sasaki, Masami Watanabe, Toshinori Omi

Research output: Contribution to journalArticle

Abstract

Mutations in the p53 gene are associated with more than half of all human cancers. These mutations often cause a disruption of the tumor-suppressor function of p53 and induce genomic instabilities. Wild-type p53 requires tetramerization to function as an initiator of cell cycle arrest and apoptosis. Although alterations in p53 tetramerization caused by mutation have been well studied, there are few cell lines containing an endogenous mutation in the tetramerization domain of p53. Here, we report the discovery of a canine mammary gland tumor cell line CTB-m2, which contains the Leu332Gln (L332Q) mutation corresponding to Leu344 in the tetramerization domain of human p53. Although CTB-m2 cells are genetically heterozygous for the Leu332Gln mutation, the mutant mRNA was almost exclusively expressed. CTB-m2 cells showed enhanced cell proliferation compared to wild-type p53-expressing CTB-m cells of the same lineage. A p53 tetramerization reporter assay showed that the ability of the p53 mutant to form tetramers was signifcantly lower than that of wild-type p53. An immunoblot analysis of cross-linked p53 oligomerized forms demonstrated that the L332Q mutant lacked the ability to form tetramers but retained the ability to form dimers. These data suggest that the p53 mutant cell line CTB-m2 could be a useful tool for analyzing the precise tetramerization mechanisms of p53 and verifying the effects of therapeutic agents against tumors expressing p53 mutants that lack the ability to tetramerize.

Original languageEnglish
Pages (from-to)488-494
Number of pages7
JournalOncology Reports
Volume40
Issue number1
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Human Mammary Glands
Tumor Cell Line
Canidae
Breast Neoplasms
Mutation
Cell Line
Neoplasms
Genomic Instability
p53 Genes
Therapeutic Uses
Cell Lineage
Cell Cycle Checkpoints
Cell Proliferation
Apoptosis
Messenger RNA

Keywords

  • Canine
  • Mammary gland tumor
  • Mutation
  • P53
  • Tetramerization

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ochiai, K., Azakami, D., Morimatsu, M., Hirama, H., Kawakami, S., Nakagawa, T., ... Omi, T. (2018). Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line. Oncology Reports, 40(1), 488-494. https://doi.org/10.3892/or.2018.6409

Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line. / Ochiai, Kazuhiko; Azakami, Daigo; Morimatsu, Masami; Hirama, Hinako; Kawakami, Shota; Nakagawa, Takayuki; Michishita, Masaki; Egusa, Ai S.; Sasaki, Takanori; Watanabe, Masami; Omi, Toshinori.

In: Oncology Reports, Vol. 40, No. 1, 01.07.2018, p. 488-494.

Research output: Contribution to journalArticle

Ochiai, K, Azakami, D, Morimatsu, M, Hirama, H, Kawakami, S, Nakagawa, T, Michishita, M, Egusa, AS, Sasaki, T, Watanabe, M & Omi, T 2018, 'Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line', Oncology Reports, vol. 40, no. 1, pp. 488-494. https://doi.org/10.3892/or.2018.6409
Ochiai, Kazuhiko ; Azakami, Daigo ; Morimatsu, Masami ; Hirama, Hinako ; Kawakami, Shota ; Nakagawa, Takayuki ; Michishita, Masaki ; Egusa, Ai S. ; Sasaki, Takanori ; Watanabe, Masami ; Omi, Toshinori. / Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line. In: Oncology Reports. 2018 ; Vol. 40, No. 1. pp. 488-494.
@article{2a406f4ed14b434e8b72b12d43bbef0d,
title = "Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line",
abstract = "Mutations in the p53 gene are associated with more than half of all human cancers. These mutations often cause a disruption of the tumor-suppressor function of p53 and induce genomic instabilities. Wild-type p53 requires tetramerization to function as an initiator of cell cycle arrest and apoptosis. Although alterations in p53 tetramerization caused by mutation have been well studied, there are few cell lines containing an endogenous mutation in the tetramerization domain of p53. Here, we report the discovery of a canine mammary gland tumor cell line CTB-m2, which contains the Leu332Gln (L332Q) mutation corresponding to Leu344 in the tetramerization domain of human p53. Although CTB-m2 cells are genetically heterozygous for the Leu332Gln mutation, the mutant mRNA was almost exclusively expressed. CTB-m2 cells showed enhanced cell proliferation compared to wild-type p53-expressing CTB-m cells of the same lineage. A p53 tetramerization reporter assay showed that the ability of the p53 mutant to form tetramers was signifcantly lower than that of wild-type p53. An immunoblot analysis of cross-linked p53 oligomerized forms demonstrated that the L332Q mutant lacked the ability to form tetramers but retained the ability to form dimers. These data suggest that the p53 mutant cell line CTB-m2 could be a useful tool for analyzing the precise tetramerization mechanisms of p53 and verifying the effects of therapeutic agents against tumors expressing p53 mutants that lack the ability to tetramerize.",
keywords = "Canine, Mammary gland tumor, Mutation, P53, Tetramerization",
author = "Kazuhiko Ochiai and Daigo Azakami and Masami Morimatsu and Hinako Hirama and Shota Kawakami and Takayuki Nakagawa and Masaki Michishita and Egusa, {Ai S.} and Takanori Sasaki and Masami Watanabe and Toshinori Omi",
year = "2018",
month = "7",
day = "1",
doi = "10.3892/or.2018.6409",
language = "English",
volume = "40",
pages = "488--494",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line

AU - Ochiai, Kazuhiko

AU - Azakami, Daigo

AU - Morimatsu, Masami

AU - Hirama, Hinako

AU - Kawakami, Shota

AU - Nakagawa, Takayuki

AU - Michishita, Masaki

AU - Egusa, Ai S.

AU - Sasaki, Takanori

AU - Watanabe, Masami

AU - Omi, Toshinori

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Mutations in the p53 gene are associated with more than half of all human cancers. These mutations often cause a disruption of the tumor-suppressor function of p53 and induce genomic instabilities. Wild-type p53 requires tetramerization to function as an initiator of cell cycle arrest and apoptosis. Although alterations in p53 tetramerization caused by mutation have been well studied, there are few cell lines containing an endogenous mutation in the tetramerization domain of p53. Here, we report the discovery of a canine mammary gland tumor cell line CTB-m2, which contains the Leu332Gln (L332Q) mutation corresponding to Leu344 in the tetramerization domain of human p53. Although CTB-m2 cells are genetically heterozygous for the Leu332Gln mutation, the mutant mRNA was almost exclusively expressed. CTB-m2 cells showed enhanced cell proliferation compared to wild-type p53-expressing CTB-m cells of the same lineage. A p53 tetramerization reporter assay showed that the ability of the p53 mutant to form tetramers was signifcantly lower than that of wild-type p53. An immunoblot analysis of cross-linked p53 oligomerized forms demonstrated that the L332Q mutant lacked the ability to form tetramers but retained the ability to form dimers. These data suggest that the p53 mutant cell line CTB-m2 could be a useful tool for analyzing the precise tetramerization mechanisms of p53 and verifying the effects of therapeutic agents against tumors expressing p53 mutants that lack the ability to tetramerize.

AB - Mutations in the p53 gene are associated with more than half of all human cancers. These mutations often cause a disruption of the tumor-suppressor function of p53 and induce genomic instabilities. Wild-type p53 requires tetramerization to function as an initiator of cell cycle arrest and apoptosis. Although alterations in p53 tetramerization caused by mutation have been well studied, there are few cell lines containing an endogenous mutation in the tetramerization domain of p53. Here, we report the discovery of a canine mammary gland tumor cell line CTB-m2, which contains the Leu332Gln (L332Q) mutation corresponding to Leu344 in the tetramerization domain of human p53. Although CTB-m2 cells are genetically heterozygous for the Leu332Gln mutation, the mutant mRNA was almost exclusively expressed. CTB-m2 cells showed enhanced cell proliferation compared to wild-type p53-expressing CTB-m cells of the same lineage. A p53 tetramerization reporter assay showed that the ability of the p53 mutant to form tetramers was signifcantly lower than that of wild-type p53. An immunoblot analysis of cross-linked p53 oligomerized forms demonstrated that the L332Q mutant lacked the ability to form tetramers but retained the ability to form dimers. These data suggest that the p53 mutant cell line CTB-m2 could be a useful tool for analyzing the precise tetramerization mechanisms of p53 and verifying the effects of therapeutic agents against tumors expressing p53 mutants that lack the ability to tetramerize.

KW - Canine

KW - Mammary gland tumor

KW - Mutation

KW - P53

KW - Tetramerization

UR - http://www.scopus.com/inward/record.url?scp=85047900767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047900767&partnerID=8YFLogxK

U2 - 10.3892/or.2018.6409

DO - 10.3892/or.2018.6409

M3 - Article

C2 - 29750295

AN - SCOPUS:85047900767

VL - 40

SP - 488

EP - 494

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -